Clinical trials: T-lymphocytes
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive
- Trial name
- ANCILE-30 (NCT07729397)
- Testing
- Autologous C7R.CD30-CAR-EBVSTs
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Methodist Hospital Research Institute
Diabetes Mellitus, Healthy
Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus
Type 1 diabetes mellitus is an autoimmune disease in which the body's immune cells attack the insulin-producing cells of the pancreas.
- Trial name
- NCT00001985
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Lymphocytic Leukemia
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06481735
- Testing
- TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Synovial Sarcoma, Myxoid Liposarcoma
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
- Trial name
- NCT04044768
- Testing
- afamitresgene autoleucel (previously ADP-A2M4)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 52 people
- Sponsor
- USWM CT, LLC
Chronic Myeloproliferative Disorders, Leukemia
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00800150
- Testing
- fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Leukemia
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00430118
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 76 sites in Austria, Germany and 1 more
- Volunteers
- 4,559 people
- Sponsor
- University Hospital Schleswig-Holstein
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
It is a treatment that activates and strengthens the immune system against cancer. Recently, T cell receptors have been genetically rearranged by adaptive T cell therapies, which are promising in the fight against cancer, and are…
- Trial name
- ISIKOK-19 (NCT04206943)
- Testing
- Car-T Cell Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Acibadem University
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04532268
- Testing
- Humanized CD19 CAR-T cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Solid Tumor
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed.
- Trial name
- NCT02992210
- Testing
- 4SCAR-GD2
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Sarcoma, HER-2 Protein Overexpression
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this…
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT04995003
- Testing
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Bone Marrow Failure Syndrome
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
- Trial name
- NCT06787560
- Testing
- CD7 CAR-T cells injection, Allo-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
T Cell Deficiency
Functional Exhaustion of T Cells in COVID19 Patients
The primary end-point of our prospective, observational study is to count T cells in patients with laboratory-confirmed COVID-19 and healthy controls.
- Trial name
- NCT04470323
- Testing
- Flow cytometry
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Nasopharyngeal Cancer, EBV Infections
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer.
- Trial name
- CLANC (NCT00078546)
- Testing
- EBV specific CTL Infusion, Anti CD45 monoclonal antibody
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00707083
- Testing
- dexamethasone, mercaptopurine, methotrexate
- Where
- 2 sites in China
- Volunteers
- 2,231 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma…
- Conditions
- NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer
- Trial name
- NCT02869217
- Testing
- Cyclophosphamide, TBI-1301, Fludarabine
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Neuroblastoma
A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed…
- Trial name
- NCT01802138
- Testing
- Activated T lymphocyte
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Seoul National University Hospital
Non-hodgkin's Lymphoma
Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
This is a study of patients with relapsed or refractory non-Hodgkin's lymphoma. To evaluate the safety and efficacy of SL1904B in patients with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT04447547
- Testing
- CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.